The MOLOGEN AG shares have been traded in the General Standard on the Regulated Market at Frankfurt Stock Exchange so far and are now being admitted to the part of the Regulated Market in which additional requirements have to be met (Prime Standard) with immediate effect.
Following the switch to the Prime Standard, MOLOGEN AG is listed in the stock market segment in which Deutsche Börse makes the highest transparency and disclosure requirements. The conditions for inclusion in one of Deutsche Börse's specialised indices have now been met too.
Dr Matthias Schroff, Chairman of the Executive Board of MOLOGEN AG: "I am delighted about the switch to the Prime Standard. Our aim is to make our share more interesting to shareholders in the long term. This step will attract greater attention from investors, while increasing share liquidity."
MOLOGEN AG has recently achieved success in the development of cancer drugs: patients' response to the company's innovative new cancer drug in the clinical study exceeded the expectations. The provisional results show that the drug MGN1703 exhibits a positive safety profile with all the patients who were treated with different doses of the cancer drug for up to 12 weeks.
About Mologen
MOLOGEN AG, a biopharmaceutical company based in Berlin, specializes in the research and development of innovative medicines based on DNA structures. Activities focus on product developments for the treatment of cancer and vaccines for serious infections
MOLOGEN was founded in 1998 and is among the few biotechnology companies in the world with well-tolerated, DNA-based cancer treatment in the clinical development stage.
MOLOGEN AG shares are listed in the Prime Standard of Deutsche Börse (ISIN DE 0006637200).
